848086-72-6

Upstream product

• 848086-71-5 5-hydroxy-1,2,3,4-tetrahydro-naphthalene-1-carboxylic acid methyl ester 
• 612499-61-3 (3-bromopropyl)({ [2-chloro-3-(trifluoromethyl)phenyl]methyl})(2,2-diphenylethyl)amine 
• 405102-95-6 5-(benzyloxy)-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid 
• 405911-35-5 N-(2,2-diphenylethyl)-N-(2-chloro-trifluoromethylbenzyl)amine 
• 848086-70-4 5-benzyloxy-1,2,3,4-tetrahydro-naphthalene-1-carbaldehyde 
• 93118-03-7 2-chloro-3-trifluoromethylbenzaldehyde 

Downstream Products

• 848171-53-9 5-{3-[(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-1,2,3,4-tetrahydro-naphthalene-1-carboxylic acid 
• 848086-69-1 5-{3-[(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-1,2,3,4-tetrahydro-naphthalene-1-carboxylic acid hydrochloride 

Relevant academic research and scientific papers

The discovery of tertiary-amine LXR agonists with potent cholesterol efflux activity in macrophages

The liver X receptors (LXR) play a key role in cholesterol homeostasis and lipid metabolism. SAR studies around tertiary-amine lead molecule 2, an LXR full agonist, revealed that steric and conformational changes to the acetic acid and propanolamine groups produce dramatic effects on agonist efficacy and potency. The new analogs possess good functional activity, demonstrating the ability to upregulate LXR target genes, as well as promote cholesterol efflux in macrophages.

COMPOUNDS AND METHODS

Disclosed are compounds and pharmaceutically acceptable salts thereof, useful as LXR agonists.